Prof. Dr. med. Gunther Hartmann
Institute of Clinical Chemistry & Clinical Pharmacology
gunther.hartmann@ukbonn.de View member: Prof. Dr. med. Gunther Hartmann
American journal of respiratory and critical care medicine
RATIONALE: Mucus plugging causes airflow obstruction, morbidity, and mortality in chronic respiratory diseases. Charcot-Leyden crystals (CLCs), formed from eosinophil-derived Galectin-10, are frequently observed in pathologic mucus, but their role in disease is unclear.
OBJECTIVES: To define the prevalence, inflammatory context, and functional role of CLCs in mucus plugs, using acute allergic bronchopulmonary aspergillosis (ABPA) as a model of eosinophilic muco-obstructive disease.
METHODS: Airway samples from 19 patients with acute ABPA and 61 disease controls were analyzed for CLCs and Galectin-10. Paired samples from plugged and unplugged bronchial mucosal biopsies defined the spatial relationship between CLCs and inflammation. A novel mouse model demonstrated the contribution of CLCs to airway obstruction and inflammation and enabled evaluation of CLC-directed imaging and therapy.
MEASUREMENTS AND MAIN RESULTS: Airway CLCs were a sensitive and specific marker of acute ABPA. CLC-containing mucus plugs were surrounded by a localized type 2 inflammatory niche, alongside eosinophils, neutrophils and extracellular traps, whereas inflammation was minimal in unplugged airways from the same patients, or plugs lacking CLCs. In mice, CLC-containing plugs induced persistent airway obstruction and local inflammation, both reduced by a crystal-dissolving anti-Galectin-10 antibody. Galectin-10 concentrations provided a quantitative biomarker of acute ABPA, while a CLC-targeted positron emission tomography tracer enabled noninvasive visualization of crystal-rich plugs.
CONCLUSIONS: CLC-containing mucus plugs form focal inflammatory niches in acute ABPA, and experimental CLC deposition is sufficient to promote persistent airway obstruction and inflammation. These findings identify CLCs as a biomarker, imaging target, and tractable therapeutic target in eosinophilic muco-obstructive airway disease.
© The Author(s) 2026. Published by Oxford University Press on behalf of the American Thoracic Society.
PMID: 43055350
Institute of Clinical Chemistry & Clinical Pharmacology
gunther.hartmann@ukbonn.de View member: Prof. Dr. med. Gunther Hartmann